Literature DB >> 33716456

Percutaneous Left Atrial Appendage Closure Confirmed by Intra-Procedural Transesophageal Echocardiography under Local Anesthesia: Safety and Clinical Efficacy.

Binhao Wang1, Zhao Wang2, Bin He1, Guohua Fu1, Mingjun Feng1, Jing Liu1, Yibo Yu1, Xianfeng Du1, Huimin Chu1.   

Abstract

BACKGROUND: Percutaneous left atrial appendage closure (LAAC) is usually performed under general anesthesia (GA) guided by transesophageal echocardiography (TEE), or under local anesthesia (LA) guided by intracardiac echocardiography (ICE). GA is known to carry some disadvantages. It is sometimes technically challenging to obtain adequate imaging of the left atrial appendage (LAA) with LAAC guided by ICE. This study aimed to assess the safety and clinical efficacy of LAAC guided by TEE under LA in patients with non-valvular atrial fibrillation (AF).
METHODS: A total of 159 patients (70.5 ± 8.2 years; 66% male) with AF who had a high risk of stroke and bleeding or who had contraindications for oral anticoagulation underwent LAAC under LA. TEE or computed tomography (CT) follow-up was scheduled approximately 6 weeks after the procedure. Patients were followed to assess ischemic stroke and major bleeding events.
RESULTS: The LAA was successfully occluded in 152 patients (95.6%). There were 2 (1.3%) periprocedural major adverse events. A total of 142 patients (93.4%) finished TEE or CT follow-up. Thrombus formation as seen on the device was documented in 2 patients. All of the LAAs were completely sealed with the absence of flow or with minimal flow. The median follow-up period was 522 days, resulting in a total of 216 patient-years. Ischemic stroke occurred in 4 patients. The annual ischemic stroke rate was 1.9/100 person-years. Major bleeding occurred in 2 patients. The annual major bleeding rate was 1.9/100 person-years.
CONCLUSIONS: In this study, percutaneous LAAC using TEE under LA was safe and showed encouraging results for stroke prevention and major bleeding reduction.

Entities:  

Keywords:  Atrial fibrillation; Local anesthesia; Major bleeding; Percutaneous left atrial appendage closure; Stroke prevention

Year:  2021        PMID: 33716456      PMCID: PMC7953125          DOI: 10.6515/ACS.202103_37(2).20200327A

Source DB:  PubMed          Journal:  Acta Cardiol Sin        ISSN: 1011-6842            Impact factor:   2.672


  24 in total

1.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors:  Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal:  Chest       Date:  2010-03-18       Impact factor: 9.410

2.  Contrast-free, echocardiography-guided left atrial appendage occlusion (LAAo): a propensity-matched comparison with conventional LAAo using the AMPLATZER™ Amulet™ device.

Authors:  Alexander Sedaghat; Baravan Al-Kassou; Vivian Vij; Dominik Nelles; Marko Stuhr; Robert Schueler; Heyder Omran; Jan Wilko Schrickel; Christoph Hammerstingl; Georg Nickenig
Journal:  Clin Res Cardiol       Date:  2018-12-10       Impact factor: 5.460

3.  Minimalistic Approach to Left Atrial Appendage Occlusion Using the LAmbre Device.

Authors:  Chak-Yu So; Yat-Yin Lam; Gary Shing-Him Cheung; Christy K Y Chan; Shaojie Chen; Anna Kin-Yin Chan; Jai-Wun Park; Boris Schmidt; Bryan P Yan
Journal:  JACC Cardiovasc Interv       Date:  2018-06-11       Impact factor: 11.195

4.  General anaesthesia is associated with adverse cardiac outcome after endovascular aneurysm repair.

Authors:  E J Bakker; K M van de Luijtgaarden; F van Lier; T M Valentijn; S E Hoeks; M Klimek; H J M Verhagen; R J Stolker
Journal:  Eur J Vasc Endovasc Surg       Date:  2012-05-22       Impact factor: 7.069

5.  Prolonged QT interval predicts cardiac and all-cause mortality in the elderly. The Rotterdam Study.

Authors:  M C de Bruyne; A W Hoes; J A Kors; A Hofman; J H van Bemmel; D E Grobbee
Journal:  Eur Heart J       Date:  1999-02       Impact factor: 29.983

6.  Amplatzer left atrial appendage occlusion: single center 10-year experience.

Authors:  Fabian Nietlispach; Steffen Gloekler; René Krause; Samera Shakir; Michael Schmid; Ahmed A Khattab; Peter Wenaweser; Stephan Windecker; Bernhard Meier
Journal:  Catheter Cardiovasc Interv       Date:  2013-03-22       Impact factor: 2.692

7.  Hypotension after induction of general anesthesia: occurrence, risk factors, and therapy. A prospective multicentre observational study.

Authors:  Ondrej Jor; Jan Maca; Jirina Koutna; Michaela Gemrotova; Tomas Vymazal; Martina Litschmannova; Pavel Sevcik; Petr Reimer; Vera Mikulova; Michaela Trlicova; Vladimir Cerny
Journal:  J Anesth       Date:  2018-07-19       Impact factor: 2.078

8.  Left atrial appendage closure with the Watchman device using intracardiac vs transesophageal echocardiography: Procedural and cost considerations.

Authors:  Majd E Hemam; Kenji Kuroki; Paul A Schurmann; Amish S Dave; Diego A Rodríguez; Luis C Sáenz; Vivek Y Reddy; Miguel Valderrábano
Journal:  Heart Rhythm       Date:  2019-03       Impact factor: 6.343

9.  Anaesthetic management of transcatheter aortic valve implantation: results from the Italian CoreValve registry.

Authors:  A Sonia Petronio; Cristina Giannini; Marco De Carlo; Francesco Bedogni; Antonio Colombo; Corrado Tamburino; Silvio Klugmann; Arnaldo Poli; Fabio Guarracino; Marco Barbanti; Azeem Latib; Nedy Brambilla; Claudia Fiorina; Giuseppe Bruschi; Paola Martina; Federica Ettori
Journal:  EuroIntervention       Date:  2016-06-20       Impact factor: 6.534

10.  Direct Comparison of Low-Dose Dabigatran and Rivaroxaban for Effectiveness and Safety in Patients with Non-Valvular Atrial Fibrillation.

Authors:  Shih-Wei Meng; Ting-Tse Lin; Min-Tsun Liao; Ho-Min Chen; Chao-Lun Lai
Journal:  Acta Cardiol Sin       Date:  2019-01       Impact factor: 2.672

View more
  1 in total

1.  Percutaneous Left Atrial Appendage Closure Using an Occluder Device: A Single Center Experience.

Authors:  Isaiah C Lugtu; Wen-Han Cheng; Shih-Lin Chang; Shin-Huei Liu; Li-Wei Lo; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2022-05       Impact factor: 1.800

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.